Skip to main content

Table 3 Cobimetinib dose modification after the first event of serous retinopathy in the cobimetinib plus vemurafenib arm

From: Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Action taken with cobimetinib

All patients with serous retinopathy events (n = 63)

Patients with grade 1 events (n = 36)

Patients with grade 2 events (n = 20)

Patients with grade 3 events (n = 6)

Patients with grade 4 events (n = 1)

All

Resolved

All

Resolved

All

Resolved

All

Resolved

All

Resolved

Dose not changed, n

30

12

26

10

3

1

1

1

0

0

Dose reduced, n

18

16

4

3

13

12

1

1

0

0

Drug interrupted, n

10

5

5

3

2

0

3

2

0

0

Drug withdrawn, n

4

1

0

0

2

1

1a

0

1a

0

Unknown, n

1

0

1

0

0

0

0

0

0

0

  1. aPatients had events that were considered “recovering/resolving”